CytRx Corporation, a developer of molecular medicines for the treatment of metabolic diseases, announced today that it won a $222,000 grant from the National Institute of Diabetes and Digestive and Kidney Diseases to develop a treatment of type 2 diabetes and obesity.Â
The Small Business Innovative Research grant will allow researchers to develop inhibitors to fatty acid synthase, a component which plays a significant role in weight gain and insulin responsiveness in type 2 diabetes.Â
The grant supported studies will be conducted by Jerry W. Skiles, Director of Chemistry, at CytRx’s Drug Discovery research lab in Worcester.Â
